No abstract

AimsThere are limited studies on phase angle and sarcopenia in continuous ambulatory peritoneal dialysis patients. So, we want to explore the association between phase angle and sarcopenia and find a more sensitive indicator for diagnosing sarcopenia.MethodsWe included 101 continuous ambulatory peritoneal dialysis patients from March 2022 to August 2022 and measured the phase angle and body composition by bioelectrical impedance analysis. All patients had their handgrip strength measured. Then, we divided patients into the sarcopenia (n = 30) group and non-sarcopenia (n = 71) group according to the sarcopenia diagnostic strategy formulated by the Asian Working Group for Sarcopenia. We used logistic regression to explore the risk factors of sarcopenia. We applied Receiver-operating characteristics curves to determine the diagnostic accuracy of these risk factors.ResultsAfter adjustments for sex, age, diabetes, BMI, extracellular water ratio, extra water, serum creatinine, total kt/v, and residual kt/v, phase angle correlated to handgrip strength and lowered limb muscle mass but not to skeletal muscle mass, upper arm muscle circumference, upper limb muscle mass and appendicular skeletal muscle mass index. In the multivariate logistic model, low phase angle and older age are risk factors for sarcopenia. The AUROC of phase angle for sarcopenia is 0.79 (95%CI, 0.70–0.86, P < 0.01) for both sexes, 0.70 and 0.85 for females and males. After we combined age and phase angle as diagnostic indicators of sarcopenia, the AUROC is 0.91 (95%CI, 0.83–0.96, P < 0.0001) in both sexes, 0.89 and 0.93 for females and males.ConclusionThis study illustrates that age 52 or older is an independent risk factor for sarcopenia in continuous ambulatory peritoneal dialysis patients. Phase angle can act as a predictor of sarcopenia in those patients. But the combination of age and phase angle is more valuable in diagnosing sarcopenia.

Aims:  Limited studies on phase angle (PhA) and sarcopenia in continuous ambulatory peritoneal dialysis (CAPD) patients. We want to explore the association between PhA and sarcopenia and clarify its significance and value in diagnosing sarcopenia. Methods: We included 87 CAPD patients. We measured the PhA and body composition by bioelectrical impedance analysis. All patients had their handgrip strength (HGS) measured. Then, we divided patients into the sarcopenia (n=25) group and non-sarcopenia(n=62) group according to the sarcopenia diagnostic strategy formulated by the Asian Working Group for Sarcopenia. Results : Univariate analysis shows PhA is positively associated with HGS, skeletal muscle mass (SMM), and Upper arm muscle circumference (AMC). After adjustments for sex, age, diabetes, BMI, extracellular water ratio(E/T), extra water (OH), serum creatinine, total kt/v, and residual kt/v, PhA remains correlated to HGS and AMC, but not to SMM. In the multivariate logistic model, PhA is not correlated to sarcopenia. The AUROC of PhA for sarcopenia is 0.76(95% CI, 0.65-0.86, P<0.01, fig 3). The optimal cut-off value is identified as ≤5.25(sensitivity 74%, specificity 76%). Conclusion : This study illustrates that older age and higher total kt/v are risk factors for sarcopenia. PhA is positively associated with HGS and AMC but not with sarcopenia in CAPD patients. These results suggest that PhA can predict muscle mass and strength in CAPD patients, but its diagnosis value for sarcopenia needs more studies.